Isabel Echavarría

792 total citations
14 papers, 142 citations indexed

About

Isabel Echavarría is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Isabel Echavarría has authored 14 papers receiving a total of 142 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Isabel Echavarría's work include Advanced Breast Cancer Therapies (6 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Isabel Echavarría is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Isabel Echavarría collaborates with scholars based in Spain, Peru and United States. Isabel Echavarría's co-authors include Miguel Martín, Yolanda Jerez, Sara López‐Tarruella, Iván Márquez‐Rodas, Fernando Moreno, José Á. García-Sáenz, Marı́a del Monte-Millán, Blanca Herrero, Ana Herrero and Rocío Ramos‐Medina and has published in prestigious journals such as BMC Genomics, Breast Cancer Research and Treatment and Future Oncology.

In The Last Decade

Isabel Echavarría

14 papers receiving 142 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Isabel Echavarría Spain	8	82	47	46	43	17	14	142
Lillian M. Smyth United States	7	92 1.1×	46 1.0×	62 1.3×	39 0.9×	28 1.6×	24	166
Fernanda Mosele France	5	72 0.9×	53 1.1×	79 1.7×	45 1.0×	9 0.5×	8	131
Theodora Goulioti Belgium	8	84 1.0×	45 1.0×	60 1.3×	43 1.0×	7 0.4×	19	141
Hannah Dzimitrowicz United States	5	103 1.3×	47 1.0×	47 1.0×	29 0.7×	31 1.8×	12	150
Kerstie Johnson United Kingdom	6	64 0.8×	27 0.6×	42 0.9×	114 2.7×	24 1.4×	12	163
Marni B. McClure Japan	5	41 0.5×	29 0.6×	41 0.9×	67 1.6×	8 0.5×	7	123
Tiziano Bernasocchi United States	5	40 0.5×	32 0.7×	43 0.9×	77 1.8×	11 0.6×	6	126
Alejandro Falcón Spain	6	89 1.1×	44 0.9×	24 0.5×	54 1.3×	14 0.8×	29	135
Lucia Mentuccia Italy	8	133 1.6×	63 1.3×	75 1.6×	37 0.9×	10 0.6×	22	192
Mohammad Atiq United States	6	88 1.1×	64 1.4×	26 0.6×	54 1.3×	12 0.7×	21	155

Countries citing papers authored by Isabel Echavarría

Since Specialization

Citations

This map shows the geographic impact of Isabel Echavarría's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Echavarría with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Echavarría more than expected).

Fields of papers citing papers by Isabel Echavarría

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabel Echavarría. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Echavarría. The network helps show where Isabel Echavarría may publish in the future.

Co-authorship network of co-authors of Isabel Echavarría

This figure shows the co-authorship network connecting the top 25 collaborators of Isabel Echavarría. A scholar is included among the top collaborators of Isabel Echavarría based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabel Echavarría. Isabel Echavarría is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Sánchez-Bayona, Rodrigo, Ana Sánchez, Isabel Echavarría, et al.. (2024). Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort. Breast Cancer Research and Treatment. 206(3). 551–559. 7 indexed citations

García-Sáenz, José Á., Isabel Blancas, Isabel Echavarría, et al.. (2023). SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022). Clinical & Translational Oncology. 25(9). 2665–2678. 9 indexed citations

Echavarría, Isabel, J. Corral, Fernando Henao, et al.. (2022). SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021). Clinical & Translational Oncology. 24(4). 724–732. 5 indexed citations

López‐Tarruella, Sara, et al.. (2022). How we Treat HR-Positive, HER2-Negative Early Breast Cancer. Future Oncology. 18(8). 1003–1022. 16 indexed citations

Martín, Andrés J. Muñoz, et al.. (2021). Venous thromboembolism incidence in cancer patients with germline BRCA mutations. Clinical & Translational Oncology. 24(1). 154–158. 1 indexed citations

Jerez, Yolanda, et al.. (2020). Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer. Future Oncology. 16(17). 1165–1177. 4 indexed citations

Picornell, Antoni C., Isabel Echavarría, Enrique L. Álvarez, et al.. (2019). Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. BMC Genomics. 20(1). 452–452. 36 indexed citations

Echavarría, Isabel, Yolanda Jerez, Miguel Martín, & Sara López‐Tarruella. (2017). Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. Breast Care. 12(5). 296–302. 6 indexed citations

Echavarría, Isabel, Sara López‐Tarruella, Iván Márquez‐Rodas, Yolanda Jerez, & Miguel Martín. (2017). Neratinib for the treatment of HER2-positive early stage breast cancer. Expert Review of Anticancer Therapy. 17(8). 669–679. 23 indexed citations

10.

López‐Tarruella, Sara, Jesús Solera, Yolanda Jerez, et al.. (2017). Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. Journal of Genetic Counseling. 27(4). 854–862. 7 indexed citations

11.

López‐Tarruella, Sara, Yolanda Jerez, Iván Márquez‐Rodas, Isabel Echavarría, & Miguel Martín. (2017). Ribociclib for the Treatment of Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer. Future Oncology. 13(24). 2137–2149. 6 indexed citations

12.

Echavarría, Isabel, Coralia Bueno, Sara López‐Tarruella, et al.. (2016). Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. Breast Cancer Research and Treatment. 162(1). 181–189. 11 indexed citations

13.

Martín, Miguel, Ana Herrero, & Isabel Echavarría. (2015). El cáncer de mama. Arbor. 191(773). a234–a234. 8 indexed citations

14.

Echavarría, Isabel, et al.. (2014). Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside. Current Breast Cancer Reports. 6(2). 79–87. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact